Potent inhibitor of VEGFR-2, -3, and -1 (IC50
values are 0.2, 0.1-0.3, and 1.2 nM respectively). Exhibits minimal activity against a panel of ~100 protein kinase. Inhibits angiogenesis and vascular permeability. Also a high affinity BCR-ABL1 (T315I) inhibitor (Ki
= 149 pM for autophosphorylated ABL1 (T315I)). Blocks proliferation of Ba/F3 cells expressing BCR-ABL1 (T315I). Orally available.
Soluble to 25 mM in DMSO
Store at +4°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
Ma and Waxman
Mol.Cancer Ther., 2008;7:79
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska et al.
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2 and 3.
Hu-Lowe et al.
Clin.Cancer Res., 2008;14:7272
The citations listed below are publications that use Tocris products. Selected citations for Axitinib include:
Showing Results 1 - 2 of 2